Microbot Medical Doubles Q2 Revenue, Sales Territories Rise to Eight and Secures U.S. Federal Contracts
MBOT•Microbot Medical achieved over 100% sequential revenue and customer growth in Q2 2026 after its April launch of the LIBERTY System at U.S. health systems. Procedure volumes climbed at initial sites, sales territories doubled to eight, and the company secured federal contracts plus Israeli marketing clearance.
1. Second Quarter Growth
Microbot Medical delivered over 100% sequential revenue and new customer growth in Q2 2026 following the full market release of the LIBERTY System on April 13. Procedure volumes also increased at limited-release sites due to site expansion and more users migrating to the robotic system.
2. Market and Contract Expansion
During Q2, the company expanded U.S. sales territories from four to eight, with plans to reach 12 by year-end 2026. It also signed an agreement with Lovell Government Services to serve the Veterans Health Administration, the Military Health System and the Indian Health Service.
3. Manufacturing and International Clearance
Microbot Medical secured Israeli marketing clearance for the LIBERTY System, marking its first approval outside the U.S. It also finalized an agreement for a second manufacturing site, enhancing production capacity for growing system volumes.
